Treatment Resistant Cancers
Targeted Cancer Therapies
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Apr 24, 2026

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
Published on: March 25, 2016
The FDA approved Beleodaq, a new histone deacetylase inhibitor, for treating relapsed or refractory peripheral T-cell lymphoma. This accelerated approval offers a new option for patients with this rare cancer.
Area of Science:
Background: